Fluid Retention Caused by Rosiglitazone Is Related to Increases in AQP2 and αENaC Membrane Expression

Figure 4

Effects of rosiglitazone and coincubation with GW9662 in mIMCD-3 cells. (a–d) The effects of rosiglitazone on PPARγ, p-PPARγ, AQP2, and αENaC. (e–h) The changes of PPARγ, p-PPARγ, AQP2, and ENaC upon coincubation with GW9662 (10 μM ROS + 5 μM GW9662). The results show that rosiglitazone at 10 μM can significantly decrease total and nuclear p-PPARγ but critically upregulated nuclear PPARγ and AQP2 and αENaC membrane transpositions. After coincubation with GW9662 (10 μM ROS + 5 μM GW9662), the effects of rosiglitazone on PPARγ, p-PPARγ, AQP2, and ENaC disappeared. The results are shown as mean ± s.e.m., . . . means compared to control; means compared to rosiglitazone.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)